Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership17,300 shares
Latest Disclosed Value $ 2,279,102
Standard Life Aberdeen plc reports 56.77% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 17,300 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $2,279,102 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 40,016 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -56.77% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,300 -22,716 -56.77 2,279 -59.84 0.0020
2026-01-16 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,016 -50,029 -55.56 5,675 -55.10 0.0088
2025-11-07 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 90,045 -28,241 -23.88 12,641 -14.98 0.0200
2025-07-24 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 118,286 -102,058 -46.32 14,867 -38.99 0.0253
2025-05-13 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 220,344 63,770 40.73 24,370 14.03 0.0475
2025-01-24 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 156,574 20,150 14.77 21,372 35.97 0.0401
2024-10-25 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 136,424 -24,723 -15.34 15,719 -29.15 0.0288
2024-08-09 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 161,147 77,935 93.66 22,185 93.32 0.0425
2024-05-09 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 83,212 -421 -0.50 11,477 4.15 0.0225
2024-01-31 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 83,633 80,420 2,502.96 11,019 2,952.35 0.0239
2023-11-07 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,213 -269 -7.73 361 10.06 0.0009
2024-06-20 2023-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 3,482 1,504 76.04 328 64.00 0.0008
2023-08-04 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,482 1,504 328 0.0008
2024-06-20 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 1,978 1,978 200 0.0005
2023-04-28 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,978 1,978 200 0.0005
2021-08-10 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -3,419 -100.00 0 -100.00
2021-05-06 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,419 255 8.06 333 9.90 0.0008
2021-02-10 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,164 346 12.28 303 11.81 0.0007
2020-10-21 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,818 -2,283 -44.76 271 -56.43 0.0007
2020-08-10 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,101 -76,461 -93.75 622 -91.19 0.0017
2020-05-13 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 81,562 -695 -0.84 7,063 -20.12 0.0224
2020-02-18 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 82,257 1,569 1.94 8,842 21.64 0.0214
2019-11-13 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 80,688 -19,608 -19.55 7,269 -14.21 0.0181
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,296 -4,719 -4.49 8,473 -8.44 0.0188
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 105,015 -5,565 -5.03 9,254 18.32 0.0201
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 110,580 -26,127 -19.11 7,821 -53.49 0.0186
2018-11-20 2018-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 136,707 136,707 16,815 0.0313
2018-11-13 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 136,707 16,815 0.0313
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.